Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Chunghwa Chemical Synthesis & Biotech Co., Ltd. (1762:TWSE), powered by AI.
Chunghwa Chemical Synthesis & Biotech Co., Ltd. is currently trading at $35.35. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Chunghwa Chemical Synthesis & Biotech Co., Ltd. on Alpha Lenz.
View Chunghwa Chemical Synthesis & Biotech Co., Ltd.'s valuation metrics on Alpha Lenz.
“Chunghwa Chemical Synthesis & Biotech Co., Ltd.'s ROE is -7.6%. Explore profitability and growth together.”
Ask for details →Chunghwa Chemical Synthesis & Biotech Co., Ltd. is a prominent player in the pharmaceutical and biotechnology industry, primarily focused on the development, manufacture, and distribution of high-quality chemical synthesis products and biotech solutions. Its operations span from producing active pharmaceutical ingredients (APIs) to delivering advanced biotech products, supporting both healthcare and research institutions. The company is known for its emphasis on innovation and strict adherence to quality standards, which helps it cater to a wide range of therapeutic areas, including oncology, neurology, and infectious diseases. Based in Taiwan, Chunghwa Chemical Synthesis & Biotech serves a global market, leveraging its state-of-the-art facilities and expertise to contribute significantly to advancements in healthcare and improving patient outcomes. By continually expanding its product portfolio and forging strategic partnerships, the company plays a vital role in addressing the ever-evolving demands of the pharmaceutical and biotechnology landscapes.
“Chunghwa Chemical Synthesis & Biotech Co., Ltd.'s ROE is -7.6%. Explore profitability and growth together.”
Ask for details →Chunghwa Chemical Synthesis & Biotech Co., Ltd. (ticker: 1762) is a company listed on TWSE in the Healthcare sector (Biotechnology).
The current price is 35.35 with a P/E ratio of -x and P/B of -x.
ROE is -7.57% and operating margin is -39.70%. Annual revenue is $805M.